Asian Journal of Pharmaceutical Research and Health Care

Open Access Open Access  Restricted Access Subscription Access

The Prognosis Value of CDH-1 Methylation-The Epigenetic Biomarker in Nasopharyngeal Carcinoma:Systematic Review and Meta-Analysis


Affiliations
1 Faculty of Biotechnology, Department of Pharmaceutical and Medical Biotechnology, Ho Chi Minh City Open University, Ho Chi Minh City − 700000, Viet Nam
2 Faculty of Biology and Biotechnology, Ho Chi Minh City University of Science, Hồ Chí Minh − 700000, Viet Nam
 

Background: The phenome of CDH-1 gene methylation has been reported to be associated with the nasopharyngeal tumorigenesis. Objective: Aiming to evaluate the association between the CDH-1 gene methylation and nasopharyngeal cancer, and its correlation could be used as an epigenetic biomarker for nasopharyngeal cancer risk based on meta-analysis. Materials and Methods: Relevant articles were identified by searching MEDLINE database. The frequency and Odds Ratio (OR) were applied to estimate the effect of CDH-1 methylation based on random-/fix-effects models. Results: Total of 12 studies, including 500 samples from NPC patients and 201 samples from non-cancerous samples, were enrolled in current study. Overall, the frequency of CDH-1 gene methylation were 48.50% and 3.09% in the case and control group, respectively. The association between the CDH-1 gene methylation and risk of NPC was also confirmed by calculating OR value of 15.33 (95% CI = 7.82-30.06), based on the fix-effects model. Additionally, the significant association was also found between the methylation of CDH-1 gene and subgroups. Conclusion: this meta-analysis provides scientific evidences to suggest the CDH-1 methylation was the potential biomarker for risk of NPC.

Keywords

CDH-1, Epigenetic Biomarker, Nasopharyngeal carcinoma, Meta-Analysis.
User
Notifications
Font Size

  • Sham JS, Wei WI, Zong YS, Choy D, Guo YQ, Luo Y, et al. Detection of subclinical nasopharyngeal carcinoma by fibreoptic endoscopy and multiple biopsy. Lancet 1990; 335(8686):371-74. https://doi.org/10.1016/01406736(90)90206-K

  • Chang CM, Yu KJ, Mbulaiteye SM, Hildesheim A, Bhatia K. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: A need for reappraisal. Virus Res. 2009; 143(2):209-21. https://doi.org/10.1016/j.virusres.2009.07.005. PMid: 19596032, PMCid: PMC2731007.

  • Mahdavifar N, Ghoncheh M, Mohammadian-Hafshejani A, Khosravi B, Salehiniya H. Epidemiology and inequality in the incidence and mortality of Nasopharynx Cancer in Asia. Osong. Public Health Res. Perspect. 2016; 7(6):360-72. https:// doi.org/10.1016/j.phrp.2016.11.002. PMid: 28053841, PMCid: PMC5194228.

  • Lao TD, Nguyen TV, Nguyen DH, Nguyen MT, Nguyen CH, Le THA. miR-141 is up-regulated in biopsies from Vietnamese patients with nasopharyngeal carcinoma. Braz. Oral. Res. 2018a; 32:e126. https://doi.org/10.1590/1807-3107bor-2018.vol32.0126. PMid: 30569973.

  • Lao TD, Nguyen DH, Le THA. Study of mir-141 and its potential targeted mRNA PTEN expression in Nasopharyngeal Carcinoma: From in Silico to initial experiment analysis. AJPRHC. 2018b; 10(3):66-74. https://doi.org/10.18311/ajprhc/2018/22341.

  • Lao TD, Le THA. Epidemiology, incidence and mortality of Nasopharynx Cancer in Southeast Asia: An update report. Adv. Life Sci. 2020; 7(2):86-90.

  • Wang LH, Wu CF, Rajasekaran N, Shin YK. Loss of tumor suppressor gene function in human cancer: An Overview. Cell Physiol. Biochem. 2018; 51(6):2647-93. https://doi.org/10.1159/000495956. PMid: 30562755.

  • Goodwin M, Yap AS. Classical cadherin adhesion molecules: Coordinating cell adhesion, signaling and the cytoskeleton. J. Mol. Histol. 2004; 35:839-44. https://doi.org/10.1007/s10735004-1833-2. PMid: 15609097.

  • Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: How does cadherin dysfunction promote tumor progression? Oncogene. 2008; 27(55):6920-29. https://doi.org/10.1038/ onc.2008.343. PMid: 19029934, PMCid: PMC2745643.

  • Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009; 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097. PMid: 19621072, PMCid: PMC2707599.

  • Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002; 21(11):1539-58. https://doi.org/10.1002/sim.1186. PMid: 12111919.

  • DerSimonian R. Meta-analysis in the design and monitoring of clinical trials. Stat. Med. 1996; 15(12):1237-48. https://doi.org/10.1002/(SICI)1097-0258(19960630)15:12<1237::AIDSIM301> 3.0.CO;2-N.

  • Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60.https://doi.org/10.1136/bmj.327.7414.557 PMid: 12958120, PMCid: PMC192859.

  • Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088101. https://doi.org/10.2307/2533446. PMid: 7786990.

  • Egger M, Davey SG, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. https://doi.org/10.1136/bmj.315.7109.629. PMid: 9310563, PMCid: PMC2127453.

  • Chang HW, Chan A, Kwong DLW, Wei WI, Sham JST, Yuen APW. Evaluation of Hypermethylated tumor suppressor genes as tumor markers in mouth and throat rinsing fluid, nasopharyngeal swab and peripheral blood of nasopharygeal carcinoma patient. Int. J. Cancer. 2003; 105:851-55. https://doi.org/10.1002/ijc.11162. PMid: 12767073.

  • Wong TS, Tang KC, Kwong DLW, Sham JST, Wei WI, Kwong YL, et al. Differential gene methylation in undifferentiated nasopharyngeal carcinoma. International Journal of Oncology. 2003; 22:869-74. https://doi.org/10.3892/ijo.22.4.869.

  • Tsao SW, Liu Y, Wang XX, Yuen PW, Leung SY, Yuen ST, et al. The association of E-cadherin expression and the methylation status of the E-cadherin gene in nasopharyngeal carcinoma cells. European Journal of Cancer. 2003; 39:524-31. https://doi.org/10.1016/S0959-8049(02)00494-X.

  • Li Z, Lin SX, Liang YJ. Influence of E-cadherin promoter methylation and mutation of beta-catenin on invasion and metastasis of nasopharyngeal carcinoma cells. Europe PMC. 2003; 25(3):238-42.

  • Li Z, Lin S, Liang YJ. Detection of gene promoter methylation and mRNA, protein expression levels of E-cadherin in nasopharyngeal carcinoma. Springer. 2003; 32(1):25.30. PMID:12760799

  • Wong TS, Kwong DLW, Sham JST, Wei WI, Kwong YL, Yuen APW. Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. Clinical Cancer Research. 2004; 10:2401-06. https://doi.org/10.1158/10780432.CCR-03-0139. PMid: 15073117.

  • Li Z, Ren Y, Lin SX, Liang YJ, Liang HZ. Association of E-cadherin and beta-catenin with metastasis in nasopharyngeal carcinoma. Europe PMC. 2004; 117(8):1232-39.

  • Tan SH, Ida H, Goh BC, Hsieh W, Loh M, Ito Y. Analyses of promoter hypermethylation for RUNX3 and other tumor suppressor genes in nasopharyngeal carcinoma. Anticancer Research. 2006; 26:4287-92.

  • Niemhom S, Kitazawa S, Kitazawa R, Maeda S, Leopairat J. Hypermethylation of epithelial-cadherin gene promoter is associated with Epstein-Barr virus in nasopharyngeal carcinoma. Cancer Detection and Prevention. 2008; 32:127-34. https://doi.org/10.1016/j.cdp.2008.05.005. PMid:18632221.

  • Ayadi W, Karray-Hakim H, Khabir A, Feki L, Charfi S, Boudawara T, et al. Aberrant methylation of p16, DLEC1, BLU and E-Cadherin gene promoters in nasopharyngeal carcinoma biopsies from tunisian patients. Anticancer Research. 2008; 28:2161-68.

  • Ran Y, Wu S, You Y. Demethylation of E-cadherin gene in nasopharyngeal carcinoma could serve as a potential therapeutic strategy. J. Biochem. 2011; 149(1):49-54. https://doi.org/10.1093/jb/mvq128.PMid: 21059597.

  • Challouf S, Ziadi S, Zaghdoudi R, Ksiaa F, Ben Gacem R, Trimeche M. Patterns of aberrant DNA hypermethylation in nasopharyngeal carcinoma in Tunisian patients. Clinica. Chimica. Acta. 2012; 413:795-802. https://doi.org/10.1016/j.cca.2012.01.018. PMid: 22296674.

  • Li LL, Shu XS, Wang ZH, Cao Y, Tao Q. Epigenetic disruption of cell signaling in nasopharyngeal carcinoma. Chin. J. Cancer. 2011; 30(4):231-39. https://doi.org/10.5732/cjc.011.10080 PMid: 21439244, PMCid: PMC4013349.

  • Jiang W, Cai R, Chen QQ. DNA Methylation biomarkers for nasopharyngeal carcinoma: Diagnostic and prognostic tools. Asian Pac. J. Cancer Prev. 2015; 16(18):8059-65. https://doi.org/10.7314/APJCP.2015.16.18.8059. PMid: 26745039.

  • Semb H, Christofori G. The tumor-suppressor functions of E-cadherin. Am. J. Hum. Genet. 1998; 63(6):1588-93. https://doi.org/10.1086/302173. PMid: 9837810, PMCid: PMC1377629.

  • Pećina-Slaus N. Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int. 2003; 3(1):17. https://doi.org/10.1186/1475-2867-3-17 PMid: 14613514, PMCid: PMC270068.

  • Huang Z, Bassil CF, Murphy SK. Methylation-specific PCR. Methods Mol. Biol. 2013; 1049:75-82. https://doi.org/10.1007/978-1-62703-547-7_7. PMid: 23913210.

  • Agodi A, Barchitta M, Quattrocchi A, Maugeri A, Vinciguerra M. DAPK1 promoter Methylation and cervical cancer risk: A systematic review and a meta-analysis. PLoS One. 2015; 10(8):e0135078. https:// doi.org/10.1371/journal.pone.0135078. PMid: 26267895, PMCid: PMC4534406.


Abstract Views: 286

PDF Views: 220




  • The Prognosis Value of CDH-1 Methylation-The Epigenetic Biomarker in Nasopharyngeal Carcinoma:Systematic Review and Meta-Analysis

Abstract Views: 286  |  PDF Views: 220

Authors

Thuan Duc Lao
Faculty of Biotechnology, Department of Pharmaceutical and Medical Biotechnology, Ho Chi Minh City Open University, Ho Chi Minh City − 700000, Viet Nam
Phuong Kim Truong
Faculty of Biotechnology, Department of Pharmaceutical and Medical Biotechnology, Ho Chi Minh City Open University, Ho Chi Minh City − 700000, Viet Nam
Hue Hong Thieu
Faculty of Biology and Biotechnology, Ho Chi Minh City University of Science, Hồ Chí Minh − 700000, Viet Nam
Thuy Ai Huyen Le
Faculty of Biotechnology, Department of Pharmaceutical and Medical Biotechnology, Ho Chi Minh City Open University, Ho Chi Minh City − 700000, Viet Nam

Abstract


Background: The phenome of CDH-1 gene methylation has been reported to be associated with the nasopharyngeal tumorigenesis. Objective: Aiming to evaluate the association between the CDH-1 gene methylation and nasopharyngeal cancer, and its correlation could be used as an epigenetic biomarker for nasopharyngeal cancer risk based on meta-analysis. Materials and Methods: Relevant articles were identified by searching MEDLINE database. The frequency and Odds Ratio (OR) were applied to estimate the effect of CDH-1 methylation based on random-/fix-effects models. Results: Total of 12 studies, including 500 samples from NPC patients and 201 samples from non-cancerous samples, were enrolled in current study. Overall, the frequency of CDH-1 gene methylation were 48.50% and 3.09% in the case and control group, respectively. The association between the CDH-1 gene methylation and risk of NPC was also confirmed by calculating OR value of 15.33 (95% CI = 7.82-30.06), based on the fix-effects model. Additionally, the significant association was also found between the methylation of CDH-1 gene and subgroups. Conclusion: this meta-analysis provides scientific evidences to suggest the CDH-1 methylation was the potential biomarker for risk of NPC.

Keywords


CDH-1, Epigenetic Biomarker, Nasopharyngeal carcinoma, Meta-Analysis.

References





DOI: https://doi.org/10.18311/ajprhc%2F2019%2F%2F25105